The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast CancerMartin Filipits, Christine Gruber-Rossipal, Elisabeth Müller‐Holzner et al.|Clinical Cancer Research|2014Cited by 219
Abstract S2-06: Survival advantage of anastrozol compared to tamoxifen for lobular breast cancer in the ABCSG-8 studyMichael Knauer, Michael Gnant, Christine Gruber et al.|Cancer Research|2015Cited by 21
Data from The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast CancerMartin Filipits, Michael Gnant, Torsten O. Nielsen et al.|Unknown|2023Cited by 0
Supplementary Table 1 from The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast CancerMartin Filipits, Michael Gnant, Torsten O. Nielsen et al.|Unknown|2023Cited by 0
Supplementary Table 1 from The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast CancerMartin Filipits, Michael Gnant, Torsten O. Nielsen et al.|Unknown|2023Cited by 0